Why Stoke Therapeutics’ Dravet syndrome drug is worth watching

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Stoke Therapeutics is nearing FDA sign-off on a groundbreaking Phase 3 clinical trial designed to prove that its experimental drug for Dravet syndrome, a severe form of epilepsy, can both reduce the frequency of seizures, and for the first time, show an improvement in the cognition and behavior of patients.

“To show improvement in cognition would set us apart from every other drug that is approved for Dravet. It’s never been done before,” Stoke CEO Ed Kaye told me.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Novel Plant-Based Estrogen Cuts Menopause Symptoms

CHICAGO — Daily treatment with a plant-based form of estrogen significantly eased vasomotor symptoms (VMS) in postmenopausal women, the primary efficacy analysis of a phase

September 18, 2024

Innovative AI model uses YouTube vlogs to identify depression signs early

An innovative depression detection model that leverages audiovisual features from YouTube vlogs.

November 8, 2023

Tandem warns iPhone app still draining insulin pump batteries

Dive Brief: Tandem Diabetes Care warned that some people are still experiencing problems with an iPhone app rapidly depleting their insulin pump battery, despite a

August 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.